AwesomeCapital
Search This Blog
Tuesday, July 23, 2019
Ionis PT Lowered to $95 at BMO Capital, Lowers Spinraza Estimates
BMO Capital analyst Do Kim lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $95.00 (from $96.00).
https://www.streetinsider.com/Analyst+Comments/Ionis+Pharmaceuticals+%28IONS%29+PT+Lowered+to+%2495+at+BMO+Capital%2C+Lowers+Spinraza+Estimates/15726988.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.